Schaeffer's Top Stock Picks for '25

2 Blue-Chip Drug Stocks in Focus Today After Earnings

Merck is lower after a missing FY guidance, Pfizer is up after a top-line beat

Managing Editor
Feb 4, 2025 at 10:06 AM
facebook X logo linkedin


Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers. Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) are both making outsized moves -- in opposite directions -- with the only common thread the ramped up option activity in response.

MRK Eyes Worst Day in 17 Years

Merck, the maker of cancer drug Keytruda, reported fiscal year guidance below estimates. The whiff overshadows an earnings beat, and the stock is down 11% to trade at $88.60 at last check, on track for its worst single-session decline since 2008. The shares earlier fell to a two-and-a-half year bottom of $87.33, and are now nursing a 30% year-over-year deficit.

Calls quickly outflanked puts this morning, with 30,000 of the former crossing the tape, 10 times the average intraday amount. Most of this attention is at a LEAPS trade at the January 2027 100-strike call. Nearer term, the April 90 and March 95 strike calls are buzzing. 

Pfizer Slowly Bouncing Back

PFE is up 2% to trade at $26.75, after the company's fourth-quarter earnings and revenue both exceeded expectations. Pfizer stock has traded in a tight range year-to-date, and today's rise isn't enough to break the consolidation. The shares have at least reclaimed their year-over-year breakeven level, and are now roughly 10% off their Nov. 15 12-month lows of $24.48.

At last check, 30,000 calls have changed hands, volume that's double the average intraday amount and nearly triple the number of puts traded. The weekly 2/7 27-strike call is the most popular by a wide margin. 

 

 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?